Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Immunocore Holdings (IMCR) Equity Ratio (2019 - 2025)

Immunocore Holdings' Equity Ratio history spans 4 years, with the latest figure at 0.36 for Q3 2025.

  • For Q3 2025, Equity Ratio rose 3.26% year-over-year to 0.36; the TTM value through Sep 2025 reached 0.36, up 3.26%, while the annual FY2024 figure was 0.36, 42.17% down from the prior year.
  • Equity Ratio for Q3 2025 was 0.36 at Immunocore Holdings, roughly flat from 0.36 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.64 in Q4 2022 and bottomed at 0.35 in Q3 2024.
  • The 4-year median for Equity Ratio is 0.36 (2025), against an average of 0.42.
  • The largest annual shift saw Equity Ratio crashed 42.17% in 2024 before it grew 3.26% in 2025.
  • A 4-year view of Equity Ratio shows it stood at 0.64 in 2022, then fell by 3.97% to 0.62 in 2023, then crashed by 42.17% to 0.36 in 2024, then grew by 0.66% to 0.36 in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Equity Ratio are 0.36 (Q3 2025), 0.36 (Q2 2025), and 0.37 (Q1 2025).